Effect of the Enteric Hormone Glucagon-Like Peptide (GLP-2) on the Intestinal Blood Flow in Patients With Short Bowel Syndrome

GLP-2 Mediated Increased SMA Blood Flow in Patients With Short Bowel Syndrome

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00673751

Enrollment

Registered

2008-05-07

Start date

Unknown

Completion date

Unknown

Last updated

2008-05-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Short Bowel Syndrome

Keywords

mesenteric blood flow, GLP-2, short bowel syndrome, Glucagon-Like Peptide 2

Brief summary

The aim of the study is to investigate the effect of the enteric hormone Glucagon-like Peptide (GLP-2) on patients with short bowel syndrome

Detailed description

previous studies have shown that GLP-2 increases mesenteric blow flow, we wish to examine the effect of subcutaneus GLP-2 on patients with short bowl syndrome. The patients will single blinded been given 450 nmol GLP-2 and isotonic saline in order to act as their own reference.

Interventions

DRUGGLP-2

450 nmol subcutaneous

DRUGPlacebo

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* clinical diagnose of short bowel syndrome 4 month of stable fase

Exclusion criteria

* activity in IBD

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026